





UNIVERSITY OF THESSALY 
SCHOOL OF MEDICINE  







“Assesing the quality of observational studies in Human 
Papilloma Virus (HPV) vaccines in cervical cancer prevention 
using the STROBE statement” 
 
 
Postgraduate Programme (MSc) 










Institutional Repository - Library & Information Centre - University of Thessaly















Figure 1 ....................................................................................................................12 
Figure 2 ....................................................................................................................13 
Figure 3 ....................................................................................................................13 
Table 1 .....................................................................................................................14 
Table 2 .....................................................................................................................17 
Table 3 .....................................................................................................................17 
Table 4 ............................................................................................................................... 18 






Institutional Repository - Library & Information Centre - University of Thessaly









PURPOSE: A substantial amount of clinical and public health knowledge originates from 
observational studies. Many analysis of epidemiological studies suggested that there is need 
for guidance in reporting observational studies and that recommendations on the reporting 
of research can improve reporting quality. The aim of this study was to evaluate the 
reporting quality of observational studies concerning cancer. 
METHODS: PubMed datatabase was searched for assess in the reporting quality of 
observational studies (cohort, case-control, cross-sectional) of Human Papilloma Virus (HPV) 
vaccines in cervical cancer prevention. Quality of reporting was evaluated according to the 
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement, 
a checklist of 34 items/ sub-items items that are considered essential for good reporting of 
Observational Studies. We also compared the reporting quality in journals endorsing the 
STROBE statement versus journals not endorsing the STROBE statement. 
RESULTS: The research strategy, using the PubMed database, identified 5645 potentially 
eligible studies. After retrieving and screening, a total of 25 articles were evaluated using 
STROBE statement as a guideline. Overall, five items/sub-items were reported by 90% or 
more of the studies. Furthermore, fourteen items/ sub-items were reported by 70% or more 
of the studies. In contrast, some items were reported only by a small fraction of articles. 
Also, 20% of articles reported < 15 items in the STROBE checklist and about 8% of articles 
reported > 23 items. Mostly articles reported about 19–22 items in the STROBE checklist. At 
last, articles published in 2016 have the highest average score (22 items), in contrast to 
articles published in 2011 have the lower average score (17 items). In comparing the 
reporting quality of the two groups of journals (endorsing or not STROBE statement) 
significant differences were seen only in two items: in the reporting of all statistical methods 
(item 12a) with p-value 0.022 and in the reporting of the source of funding (item 22) with p-
value 0.011. 
CONCLUSION: Reporting of observational studies about HPV vaccines in cervical cancer 
prevention is not clear. Our attempt to assess the reporting quality of observational  studies 
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Cancer is typically classified as a leading non-communicable disease. Cervical cancer is 
a cancer arising from the cervix. Worldwide, cervical cancer is the third most common 
cancer in women and the fourth most common cause of death in women. Cervical cancer is 
by far the most common HPV-related disease. Virtually, all cases of cervical cancer can be 
attributable to infection by high-risk HPV viruses. The most common of the high-risk strains 
of HPV are types 16 and 18, which cause about 70% of all cervical cancers.  Cervical cancer 
can often be prevented through screening in order to find any precancers so they can be 
treated. Checking the cervix by the Papanicolaou test (Pap smear) and the use of 
prophylactic vaccines against HPV have been credited with dramatically reducing the 
number of cases and mortality of cervical cancer.  
 
HPV vaccines are used to prevent HPV infection and therefore cervical cancer. All three of 
the HPV vaccines, Cervarix, Gardasil, and Gardasil 9, can prevent most cases of cervical 
cancer in females, if given before a person is exposed to the virus. Two HPV vaccines, 
Gardasil and Gardasil 9, can prevent many cases of vaginal and vulvar cancers in women, as 
well as most cases of anal cancer and genital warts in both females and males. In more 
details about their mechanism of action, Gardasil delivers HPV-6, -11, -16 and -18 L1 protein, 
conferring protection against these HPV strains, presumably through induction of humoral 
immune response. Cervarix is a non-infectious recombinant, AS04-adjuvanted vaccine that 
contains recombinant L1 protein, the major antigenic protein of the capsid, of oncogenic 
HPV types 16 and 18. The efficacy of the vaccine may be mediated by the development of 
IgG neutralizing antibodies directed against HPV-L1 capsid proteins generated as a result of 
vaccination.   
All three HPV vaccines have been tested for safety and efficacy in tens of thousands of 
people in many countries worldwide. They have been examined thoroughly with similar 
profiles in the vaccinated and control groups, regardless of age or ethnicity. So far, no 
serious side effects have been shown to be caused by the vaccines. The most common side 
effects of vaccination are headaches, pain, redness and/or swelling at the site of injection. 
These problems are similar to those commonly experienced with other vaccines. More 
severe side effects such as anaphylactic (allergic) reaction are extremely rare. So far, the rate 
of adverse side effects related to immunization was consistent with what has been seen in 
the safety studies carried out before the vaccine was approved and were similar to those 
seen with other vaccines.  
The vaccines have not been sufficiently tested during pregnancy and, therefore, should not 
be used by pregnant women. Studies show that HPV vaccines do not cause problems for 
babies born to women who were vaccinated while pregnant, but more research is still 
needed. A pregnant woman should not get any doses of either HPV vaccine until her 
pregnancy is completed.  
Moreover, HPV vaccines are approved for males in several countries. Studies have approved 
that HPV vaccines reduce the risk of genital warts and precancerous lesions caused by HPV. 
This reduction in precancerous lesions might be predicted to reduce the rates 
of penile and anal cancer in men.  
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A substantial amount of clinical and public health knowledge originates from observational 
studies (OS) (1). Observational studies have a role in research into the benefits and harms of 
medical interventions (2).  The choice of an OS design may stem from a variety of reasons 
such as ethics, restrictions in study planning, or feasibility. In addition, OS may be more 
suitable to detect rare or late adverse effects of interventions compared to randomized 
trials (3). Moreover, OS are often less expensive, and they can be performed over shorter 
time-intervals. Particularly, in cancer epidemiology, clinical trials are often not feasible 
because it is unethical to expose individuals to a potential cause of disease simply to explore 
the etiology of the disease (4).  
Observational studies are the primary type of epidemiological study used to research 
determinants of outcome. Like all epidemiological studies, an observational study observes 
causes, preventions, and treatments for outcome. In observational studies, the researcher 
observes and systematically collects information, but does not try to change the people (or 
animals, or reagents) being observed. There are 4 main types of observational studies :  
Case-control study: study originally developed in epidemiology, in which two existing groups 
differing in outcome are identified and compared on the basis of some supposed causal 
attribute. Cross-sectional study: involves data collection from a population, or a 
representative subset, at one specific point in time. Cohort study study: a particular form of 
longitudinal study where a group of patients is closely monitored over a span of time. 
Ecological study: an observational study in which at least one variable is measured at the 
group level. 
 
Many analysis of epidemiological studies suggested that there is need for guidance in 
reporting observational studies and that recommendations on the reporting of research can 
improve reporting quality. Readers need to know what was planned (and what was not), 
what was done, what was found, and what the results mean. The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) Initiative developed 
recommendations on what should be included in an accurate and complete report of an 
observational study. The STROBE Statement consists of a checklist of 22 items, confined for 
the three main analytical designs that are used in observational research: cohort, case-
control, and cross-sectional studies. These items relate to the title, abstract, introduction, 
methods, results and discussion sections of articles. Eighteen items are common to cohort 
studies, case-control studies and cross-sectional studies and four are specific to each of the 
three study designs. A general checklist and separate checklists for each of the three OS 
designs (cohort, case-control, and cross-sectional studies) are available at the web site 
www.strobestatement.org 
 
Although there is a considerable number of studies evaluating the quality of reporting in 
randomized studies, there are very few studies that critically evaluate the epidemiological 
literature according to the STROBE statement (5).  
In the present study, we critically appraise the quality of reporting of 25 OS in cervical cancer 
prevention through HPV vaccines, according to the STROBE statement. 
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DATA SOURCES, SEARCH STRATEGIES AND STUDIES SELECTION 
 
 PubMed database was searched for observational studies investigating Human Papilloma 
Virus (HPV) vaccines in cervical cancer prevention, published the last 10 years. We designed 
a PubMed formula as follows: the tag term used was “HPV vaccines” and the search was 
limited to observational studies for the last ten years, in English language and on human 
species.  
Then, the individual articles considered eligible were retrieved in full text and further 
evaluated. These articles were eligible if they were OS (i.e., cohort, case-control, and cross-
sectional), investigated HPV vaccines in cervical cancer protection, and had been published 
as full papers or short reports in a regular issue or supplement of peer-reviewed journals 
indexed in PubMed. Articles published as reviews, notes, letters, editorials were excluded.  
Figure 1 represents the study selection process. PubMed identified 5645 studies for the last 
10 years. Their titles and abstracts were assessed according to the following exclusion 
criteria: (1)limited to observational studies, (2)reviews, notes, letters, editorials, (3)non-
English language, (4)non-human studies.  
 
DATA EXTRACTION AND REPORTING ASSESSMENT TOOL 
 
The reporting quality indicates whether the necessary information for observational studies 
was sufficiently reported. The Strengthening the Reporting of Observational Studies in 
Epidemiology Statement (STROBE) checklist was used to score the reporting quality. In total, 
34 items/sub-items were considered (Table 1). In order to clarify whether an item is 
accurately reported in the articles, we took into account the guidance provided by the 
STROBE Explanation and Elaboration document (6). All the 34 items were examined in terms 
of whether they were stated or not. Items were to be scored as ‘‘yes’’ if they were stated in 
enough detail so that they allowed the reader to decide that the definition existed in the 
article. Alternative or indeterminate responses (apart from ‘‘yes’’ or ‘‘no’’) to each question 
were coded as negative responses. The studies with reporting quality scores under 13 or 
with insufficient temporal information between exposure and outcome were considered to 
be of low quality, those between 14 and 18 score of medium quality, and over 18 score of 
high quality. In the Annex is represented the process of scoring, using “1” for positive and 





The evaluation of the articles took place concerning the following sections: Introduction, 
Methods, Results, Discussion. Although, the most essential sections are the Methods and 
Results. At first, introduction items refer to the reporting of the background &rationale, and 
the objectives.  Furthermore, methodological items refer to the reporting of study design, 
setting of the study, participants’ information (eligibility criteria, sources and methods of 
selection, or matching criteria if relevant), definition of all variables used, data sources and 
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methods of measurement, any efforts to address potential sources of bias, study size, 
handling of quantitative variables in the study and performed statistical methods (i.e., 
methods used to control for confounding and to examine subgroups and interactions, 
methods of handling missing data or how loss to follow-up was addressed, methods of 
matching of cases and controls, analytical methods taking account of sampling strategy and 
any description of sensitivity analysis). Also, the items in the results section of the STROBE 
statement refer to the reporting of participants’ information (numbers of individuals at each 
stage of the study, reasons for nonparticipation at each stage, use of flow diagram), 
descriptive data (characteristics of study participants, numbers of participants with missing 
data, summary of follow-up time), outcome data (numbers of outcome events or summary 
measures), main results (unadjusted or confounder-adjusted estimates and their precision, 
presentation of 95% confidence intervals, category boundaries when continuous variables 
were categorized and translation of estimates of relative risk to absolute risk for a 
meaningful time period), and other analyses done (e.g., analysis of subgroups and 
interactions, and sensitivity analyses). Finally, the items in the discussion section refer to the 




The articles separated in two groups, those that their journals were endorsing the STROBE 
statement versus those that their journals were not endorsing the STROBE statement. 
Comparisons between the two groups were performed by calculating the p-value for the 
Chi-Square test for each item and then the Odds Ratio (OR) and the respective 95% 
confidence interval if there was any significant difference between the two groups. The 
cutoff point for statistical significance was set at the two-sided 0.05 level. Statistical analyses 





The research strategy, using the PubMed database, identified 5645 potentially eligible 
studies. Thereafter, these articles were retrieved and screened for eligibility: 5615 articles 
were excluded because of their study design, i.e. not observational studies, and 5 articles 
excluded because they did not fulfill the inclusion criteria, all of which led to a total of 25 
articles. Twelve articles were identified as duplicates. Consequently, a total of 25 articles 
were evaluated using STROBE statement as a guideline. Figure 1 displays the whole 
retrieving and screening process. A full list of the 25 reports that were included in the final 
analysis is found in the section “References”. 
 
Institutional Repository - Library & Information Centre - University of Thessaly





The 25 eligible articles were published during the period 2010–2016, after the issuing of 
STROBE statement. Cohort studies were more frequent (64%) than cross-sectional studies 





Table 1 shows the overall proportion of articles reporting each item in the STROBE checklist. 
Also, Figure 3 summarize all the results and on Table 3 are displayed the items in the 
checklist that are reported more than 75% and less than 25%. Overall, five items/sub-items 
were reported by 90% or more of the studies. The items include: 1) an informative and 
balanced summary, 2) the background and rationale of the investigation, 3) the objectives, 
4) key results in discussion, 5) the limitations of the study. Furthermore, fourrteen items/ 
sub-items were reported by 70% or more of the studies. The eight additional items were: 1) 
the study’s design in title/abstract, 2) the setting of the study (locations and relevant dates 
including periods of recruitment, exposure, follow-up, and data collection), 3) the reporting 
of eligibility criteria for participants (sources and methods of selection), 4) the description of 
all statistical methods (including those used to control for confounding), 5) the reporting of 
the study participants’ characteristics (demographic, clinical, social), 6) the details of 
outcome data, 7) the reporting of estimates and their precision in the results, 8) overall 
interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence. In contrast, some items were reported 
only by a small fraction of articles. For example, only 28% of articles provided the matching 
criteria if used, only 20% provided the reporting details about how quantitative variables 
were handled in the analyses and only 16% provided details about how missing data were 
addressed in the analyses, .The presentation of details about the number of participants 
with missing data and reporting of absolute risk for a meaningful time period were very 
uncommon, with a frequency of 4% and 8%, respectively.  
 
Table 2 shows the proportion of reported items per article. Overall, 20% of articles reported 
< 15 items in the STROBE checklist and about 8% of articles reported > 23 items. Mostly 
articles reported about 19–22 items in the STROBE checklist. 
 
Also, Figure 2 displays the average STROBE score of the studies per year. We can notice that 
articles published in 2016 have the highest average score (22 items). Although, articles 
published in 2011 have the lower average score (17 items). 
 
In comparing the reporting quality of the two groups of journals (endorsing or not STROBE 
statement) significant differences were seen only in two items: in the reporting of all 
statistical methods (item 12a) with p-value 0.022, OR 0.078 (CI 0.006-0.967)and in the 
reporting of the source of funding (item 22) with p-value 0.011, OR 0.444 (CI 0.265-0.745). 
The journals endorsing the STROBE statement appear to have a better reporting in these 
Institutional Repository - Library & Information Centre - University of Thessaly




items. None of the other items resulted in statistical differences in the two groups. An item 





The present study evaluated the reporting quality of published observational studies in HPV 
vaccines in cervical cancer prevention, using the STROBE checklist as a reference. In total, 25 
articles selected from PubMed database published from 2010 to 2016 were evaluated, 
covering a publication period of 7 years. Although the overall reporting quality was relatively 
good (17 items/sub-items were reported by 74% or more of the studies) with some items 
being reported almost consistently, there are some essential methodological aspects (such 
as matching, absolute risks, flow diagram, and missing data ) that are underreported, making 
it difficult for the reader to assess explicitly the validity of an observational study. Also, the 
journals endorsing the STROBE statement appear to have a better reporting in two items (all 
statistical methods and source of funding). 
This is a novel study and in our view the first study which analyzed observational studies in 
the field of HPV vaccines in cervical cancer prevention.  The results have direct relevance for 
authors, readers and editors of biomedical research.  A limitation of our study is that the 
literature search was restricted to PubMed database and we did not extend our search to 
more databases. However, the number of retrieved articles provided a relatively large and 





We conclude that reporting of observational studies about HPV vaccines in cervical cancer 
prevention is not clear. Our attempt to assess the reporting quality of observational  studies 
in this topic of epidemiology emphasizes the need for improvement. So, authors and editors 
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Pubmed identified 5645 
potentially relevant articles for 
the last 10 years 
30 observational studies 
remained after filtering the 
article type 
29 potentially eligible articles 
remaining by filtering the 
language 
25 articles remaining after title & 
abstract selection and included in 
the final analyses 
1 article 
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Table 1   Number of articles that fulfill each recommendation of the STROBE 
Statement. 









1a Indicate the study's design with a 
commonly used term in the title or 
the abstract 
22 (88%) 
1b Provide in the abstract an 
informative and balanced summary 







2 Explain the scientific background 
and rationale for the investigation 
being reported 
25 (100%) 
Objectives 3 State specific objectives, including 




4 Present key elements of study 
design early in the paper 
13 (52%) 
Setting 5 Describe the setting,locations, and 
relevant dates,including periods of 
recruitment,exposure,follow-up, 
and data collection 
22 (88%) 
Participants 6a Cohort study—Give the eligibility 
criteria, and the sources and 
methods of selection of 
participants. Describe methods of 
follow-up 
Case-control study—Give the 
eligibility criteria, and the sources 
and methods of case 
ascertainment and control 
selection. Give the rationale for the 
choice of cases and controls 
Cross-sectional study—Give the 
eligibility criteria, and the sources 
and methods of selection of 
participants 
21 (84%) 
6b Cohort study—For matched 
studies, give matching criteria and 
number of exposed and unexposed 
Case-control study—For matched 
studies, give matching criteria and 
the number of controls per case 
7 (28%) 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 





8 For each variable of interest, give 
sources of data and details of 
14 (56%) 
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methods of assessment 
(measurement). Describe 
comparability of assessment 
methods if there is more than one 
group 
Bias 9 Describe any efforts to address 
potential sources of bias 
6 (24%) 





11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which 




12a Describe all statistical methods, 
including those used to control for 
confounding 
21 (84%) 
12b Describe any methods used to 
examine subgroups and 
interactions 
12 (48%) 
12c Explain how missing data were 
addressed 
4 (16%) 
12d Cohort study—If applicable, explain 
how loss to follow-up was 
addressed 
Case-control study—If applicable, 
explain how matching of cases and 
controls was addressed 
Cross-sectional study—If 
applicable, describe analytical 
methods taking account of 
sampling strategy 
2 (8%) 
12e Describe any sensitivity analyses 5 (20%) 
Results Particiants 13a Report numbers of individuals at 
each stage of study—eg numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, 
included in the study, completing 
follow-up, and analysed 
17 (68%) 
13b Give reasons for non-participation 
at each stage 
3 (12%) 
13c Consider use of a flow diagram 8 (32%) 
Descriptive 
Data 
14a Give characteristics of study 
participants (eg demographic, 
clinical, social) and information on 
exposures and potential 
confounders 
21 (84%) 
14b Indicate number of participants 
with missing data for each variable 
of interest 
1 (4%) 
14c Cohort study—Summarise follow-





15 Cohort study—Report numbers of 
outcome events or summary 
measures over time 
21 (84%) 
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numbers in each exposure 
category, or summary measures of 
exposure 
Cross-sectional study—Report 
numbers of outcome events or 
summary measures 
 Main results 16a Give unadjusted estimates and, if 
applicable, confounder-adjusted 
estimates and their precision (eg, 
95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 
included 
19 (76%) 
16b Report category boundaries when 
continuous variables were 
categorized 
2 (8%) 
16c If relevant, consider translating 
estimates of relative risk into 





17 Report other analyses done—eg 
analyses of subgroups and 





Key Results 18 Summarise key results with 
reference to study objectives 
25 (100%) 
Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 




20 Give a cautious overall 
interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results 





21 Discuss the generalisability 






Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
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Table 2  Proportion of reported items per article 
Number of items in the checklist addressed Number and percentage of articles 
reporting (n=25) (%) 
0-3 items 0 (0.0%) 
3-6 items 0 (0.0%) 
7-10 items 0 (0.0%) 
11-14 items 5 (20.0%) 
15-18 items 6 (24.0%) 
19-22 items 12 (48.0%) 
23-25 items 2 (8.0%) 






Table 3  Items in the checklist usually reported and usually not reported 
Items reported by <25% of studies Items reported by >75% of studies 
Number of participants with missing data 
(item 14b) 4% 
Informative and balanced summary in abstract 
(item 1b) 100% 
Estimates of relative risk into absolute risk 
for a meaningful time period (item 16c) 8% 
Background/rationale (item 2) 100% 
Loss to follow-up addressed (item12d) 8% Key results in discussion (item 18) 100% 
Non-participation reasons (item 13b) 12% Objectives (item3) 96% 
Missing data addressed (item 12c) 16% Limitations of the study (item 19) 92% 
Sensitivity analysis (item 12e) 20% Study’s design in title/abstract (item 1a) 88% 
Quantitive variables (item 6b) 20% Setting in methods (item 5) 88% 
Bias (item 9) 24% Eligibility/matching criteria for participants 
(item 6a) 84% 
 Outcome data (item 15) 84% 
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P-value     
(two-tailed) 
Title & Abstract 
1a. Study's design in the title or the 
abstract 
88,0 (22) 100,0 (6) 84,2 (17) 0,358 
1b. Informative and balanced summary 
in the abstract 
100,0 (25) 100,0 (6) 100,0 (19) - 
Introduction 
2. Scientific background and rationale  100,0 (25) 100,0 (6) 100,0 (19) - 
3. Objectives 96,0 (24) 100,0 (6) 94,7 (18) 0,524 
Methods 
4. Key elements of study design early in 
the paper 
52,0 (13) 83,3 (5) 42,1 (8) 0,225 
5. Setting (locations, and relevant dates, 
including periods of recruitment, 
exposure, follow-up, and data 
collection) 
88,0 (22) 83,3 (5) 89,4 (17) 0,826 
6a. Eligibility criteria, and the sources 
and methods of selection of participants 
/ methods of follow-up 
84,0 (21) 83,3 (5) 84,2 (16) 0,884 
6b. Matching criteria and number of 
exposed and unexposed 
56,0 (7) 33,3 (2) 26,3 (5) 0,968 
7. Variables (outcomes, exposures, 
predictors, potential confounders, effect 
modifiers)  
56,0 (14) 33,3 (2) 63,1 (12) 0,085 
8. Data sources/ measurement 56,0 (14) 66,6 (4) 52,6 (10) 0,332 
9. Bias 24,0 (6) 16,6 (1) 26,3 (5) 0,739 
10. Study Size 48,0 (12) 50,0 (3) 52,6 (10) 0,748 
11. Quantitative Variables 20,0 (5) 16,6 (1) 21,0 (4) 0,656 
12a. All statistical methods  84,0 (21) 66,6 (4) 89,4 (17) 0,022 
12b. Methods used to examine 
subgroups and interactions 
48,0 (12) 33,3 (2) 42,1 (8) 0,467 
12c. Missing data 16,0 (4) 0,0 (0) 21,0 (4) 0,174 
12d. loss to follow-up OR matching of 
cases and controls OR sampling strategy 
8,0 (2) 0,0 (0) 10,5 (2) 0,358 
12e. sensitivity analyses 20,0 (5) 33,3 (2) 21,0 (4) 0,739 
Results 
13a. Numbers of individuals at each 
stage of study 
68,0 (17) 83,3 (5) 63,1 (12) 0,236 
13b. reasons for non-participation at 
each stage 
12,0 (3) 0,0 (0) 15,7 (3) 0,250 
13c. use of a flow diagram 32,0 (8) 50,0 (3) 26,3 (5) 0,468 
14a. Characteristics of study 
participants (eg demographic, clinical, 
social) 
84,0 (21) 100,0 (6) 78,9 (15) 0,174 
14b. Number of participants with 
missing data 
4,0 (1) 0,0 (0) 5,2 (1) 0,524 
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14c. Summarise follow-up time 24,0 (6) 50,0 (3) 15,7 (3) 0,169 
15. Outcome Data 84,0 (21) 100,0 (6) 84,2 (16) 0,250 
16a. unadjusted estimates, confounder-
adjusted estimates and their precision 
76,0 (19) 66,6 (4) 78,9 (15) 
 
0,739 
16b. Category boundaries 8,0 (2)  0,0 (0) 10,5 (2) 0,358 
16c. Translating estimates of relative 
risk into absolute risk for a meaningful 
time period 
N/A N/A N/A - 
17. Other analyses 52,0 (13) 66,6 (4) 42,1 (8) 0,144 
Discussion 
18. Key Results 100,0 (25) 100,0 (6) 100,0 (19) - 
19. Limitations 92,0 (23) 100,0 (6) 89,4 (17) 0,358 
20. Interpretation 84,0 (21) 100,0 (6) 78,9 (15) 0,174 
21. Generalisability 56,0 (14) 50,0 (3) 57,8 (11) 0,943 
Other Information 
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Annex: Results of the research 
        TITLE/ABSTRACT INTRODUCTION 





balanced summary in 
the abstract 2.Background/Rationale 3.Objectives 
                
                
1 2016 1 Lancet Oncol 1 1 1 1 
2 2015 1 BMJ 1 1 1 1 
3 2016 0 Br. J Cancer 1 1 1 1 
4 2015 0 
Am J Public 
Health 
1 1 1 1 
5 2014 0 Vaccine 0 1 1 1 
6 2014 0 
Ann Rheum 
Dis. 
1 1 1 1 
7 2015 0 Bull Cancer 1 1 1 1 
8 2014 0 
BMC Infect 
Dis. 
1 1 1 1 
9 2015 0 
J Med Internet 
Res. 
1 1 1 1 
10 2015 0 
Sex Transm 
Dis.  
1 1 1 1 
11 2014 0 
J 
Adolesc Health 
1 1 1 1 
12 2014 0 
Gynecol 
Oncol.  
0 1 1 0 
13 2013 0 
J Natl Cancer 
Inst. 
1 1 1 1 
14 2011 1 PLoS One  1 1 1 1 
15 2011 0 Vaccine 1 1 1 1 
16 2016 0 
BMC Womens 
Health 
1 1 1 1 
17 2015 0 Vaccine 1 1 1 1 
18 2015 0 CMAJ 1 1 1 1 
19 2015 1 PLoS One 1 1 1 1 
20 2014 1 PLoS One 1 1 1 1 
21 2014 0 
BMC Public 
Health. 
1 1 1 1 
22 2013 1 PLoS One 1 1 1 1 
23 2013 0 
BMC Public 
Health 
1 1 1 1 
24 2014 0 
 Asian Pac J 
Cancer Prev. 
1 1 1 1 
25 2010 0 
BMC Womens 
Health 
1 1 1 1 
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variables 12.Statistical Methods 
    6a 6b           12a 12b 12c 12d 12e 
                            
1 1 1 1 0 1 0 1 0 1 0 0 0 0 
1 1 1 1 0 1 0 1 1 1 1 0 0 1 
0 0 1 0 0 0 0 0 0 1 1 0 0 1 
1 1 1 0 1 1 0 1 1 1 1 1 1 0 
1 1 1 1 1 0 0 0 0 1 0 1 0 0 
1 1 0 1 1 1 0 0 1 1 1 0 0 0 
0 1 1 0 0 0 0 0 0 1 0 0 0 0 
1 1 1 1 1 1 0 1 1 1 1 0 0 0 
0 1 1 0 0 1 1 1 0 0 0 0 0 0 
0 0 1 0 1 1 0 0 0 1 1 0 0 0 
0 1 1 1 1 1 1 0 1 1 0 0 0 1 
1 1 1 N/A 0 0 0 1 0 0 0 0 1 0 
1 1 1 0 0 0 0 1 0 1 1 1 0 0 
1 0 0 N/A 0 1 0 0 0 0 0 0 0 0 
0 1 1 N/A 1 1 1 1 0 1 1 0 0 0 
0 1 1 N/A 1 0 1 1 0 1 0 0 0 0 
0 1 0 0 0 1 0 1 0 1 1 0 0 0 
0 1 1 1 1 1 1 1 0 1 0 0 0 1 
1 1 1 0 1 0 1 0 0 1 0 0 0 1 
1 1 1 0 1 1 0 1 0 1 1 0 0 0 
0 1 1 0 1 1 0 0 0 1 0 0 0 0 
0 1 1 N/A 0 0 0 0 0 0 0 0 0 0 
1 1 1 N/A 0 0 0 0 0 1 0 0 0 0 
0 1 0 N/A 1 0 0 0 0 1 0 1 0 0 




Institutional Repository - Library & Information Centre - University of Thessaly










13.Participants 14.Descriptive Data 15.Outcome Data 16.Main Results 17.Other analysis 
13a 13b 13c 14a 14b 14c   16a 16b 16c   
                      
1 0 1 1 0 1 1 1 0 N/A 0 
1 0 1 1 0 1 1 1 0 N/A 1 
1 0 0 1 0 0 0 1 0 N/A 1 
0 0 0 1 0 1 1 1 1 N/A 1 
1 1 1 1 0 0 1 1 0 N/A 0 
1 1 1 0 0 1 1 1 0 N/A 1 
1 0 0 0 0 0 0 1 0 N/A 0 
0 0 0 0 0 N/A 1 1 0 N/A 1 
1 0 0 1 0 0 1 1 0 N/A 1 
1 0 0 1 0 0 1 1 0 N/A 0 
0 0 0 1 0 0 1 1 0 N/A 0 
0 0 0 1 0 N/A 0 0 0 N/A 0 
1 0 0 0 0 0 1 1 0 N/A 1 
0 0 0 1 0 N/A 1 0 0 N/A 1 
1 0 0 1 0 N/A 1 1 0 N/A 1 
1 1 1 1 1 N/A 1 1 1 N/A 1 
0 0 0 1 0 0 1 1 0 N/A 0 
0 0 1 1 0 0 1 1 0 N/A 0 
1 0 0 1 0 1 1 1 0 N/A 1 
1 0 1 1 0 0 1 1 0 N/A 1 
1 0 0 1 0 1 1 0 0 N/A 0 
1 0 0 1 0 N/A 1 0 0 N/A 0 
1 0 1 1 0 N/A 1 0 0 N/A 0 
1 0 0 1 0 N/A 1 0 0 N/A 0 
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DISCUSSION OTHER INFORMATION 
18.Key 
Results 
19.Limitations 20.Interpretation 21.Generalizability 22.Funding 
          
          
1 1 1 0 1 
1 1 1 0 1 
1 1 0 1 1 
1 1 1 1 0 
1 1 1 1 1 
1 0 0 1 1 
1 1 1 0 0 
1 1 1 0 1 
1 1 1 1 1 
1 1 1 0 0 
1 1 0 0 1 
1 1 1 1 0 
1 1 1 0 1 
1 1 1 1 1 
1 1 1 0 0 
1 1 1 1 0 
1 0 0 0 0 
1 1 1 1 1 
1 1 1 1 1 
1 1 1 0 1 
1 1 1 1 1 
1 1 1 1 1 
1 1 1 0 0 
1 1 1 1 0 
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